NVO News and Press, Novo Nordisk A/S From 06/02/24

2024-06-02 10:00:00 ET More on Amgen, Structure Therapeutics, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? ...

2024-06-02 09:30:00 ET The pharmaceutical industry isn't the first place investors turn to when looking for high-growth stocks. However, some companies in the field look so promising that they could deliver well-above-average returns through the end of the decade. There are several cand...

2024-06-02 08:25:00 ET Over the last few years, some of the best-performing stocks in the broader healthcare space have been pharmaceutical businesses . A big reason for this is the rise in popularity of weight loss medications. Ozempic and Wegovy are two of the most mainstream trea...

2024-06-01 10:25:00 ET Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are the two most valuable healthcare companies in the world. Combined, they're worth nearly $1.4 trillion. And it's conceivable that their individual valuations could top $1 trillion in the future. How...

2024-06-01 09:00:00 ET More on the markets and the economy Fed may not cut rates in 2024 with inflation's slow downward pace - strategist Investors punished Salesforce after earnings. See other worst post-report reactions PCE April 2024: Personal Spending Data Confir...

2024-05-31 15:00:19 ET More on the markets Bitcoin's Fading Action Is A Huge Warning For Stock Market Liquidity S&P 500: It Is All About Liquidity SPY: Time To Be Contrarian And Underweight Hedge funds back at record exposure to Magnificent 7 S&am...

2024-05-30 16:10:00 ET Summary The global market for GLP-1 therapies now looks on pace to top $100 billion. GLP-1 pioneers such as Eli Lilly, Novo Nordisk, could be joined by new players Amgen, Altimmune, Pfizer, Viking, Roche, and privately held Boehringer Ingelheim that have GLP...

2024-05-30 11:22:06 ET More on Eli Lilly, Novo, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic Lilly's Retevmo gains appro...

2024-05-29 12:11:20 ET More on Eli Lilly, Novo Nordisk Eli Lilly: Addressing Supply Challenges Should Accelerate Growth SA Asks: Is Eli Lilly or Novo Nordisk a better investment? Novo Nordisk: The Market Is Right, Don't Fight Against It SA Asks: Who...

2024-05-29 11:50:26 ET More on AstraZeneca AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca, Daiichi Sankyo ADC misses ke...